Mr. Anand Deshpande (@anandesh), after completing his Ph. D. in Computer Science, quit his job at HP Labs in the USA. He returned to India in 1990.
And from there started a 30 Year Transformational Journey of Persistent Systems
A thread
1990- 2001
Persistent at that time was a technology provider for database product companies primarily in the USA and other western countries.
Milestones in 1999
~Reached 100 employees in
~Got 1st external investor in Intel 64 Fund
~Revenue crossed 10 Cr
(1/5)
2001-2008
~Innovation partner for software product companies
~Stayed away from the IT outsourcing services wave
~Focused on Outsourced Product Development
~Became a leader in this space
~Employees 1000
~Revenue crosses 100 Cr
~$18.8 Mn funding from Norwest & Gabriel
(2/5)
2009-2016
~Strategic partner to leading technology companies.
~Partnerships with IBM & Salesforce
~Product development to implementing Tech solution
~2010 IPO oversubscribed 93 times
~37 offices across 17 countries & 5 continents
~Employees 5000
~Revenue crosses 1000 Cr
(3/5)
2017 & Beyond
Digital Transformation: From helping software product or service companies, Persistent shifted to enterprises building software-driven business
Oncology has quietly become the largest therapy area in global pharma.
With global oncology spending expected to grow from $252 billion in 2024 to $441 billion by 2029, companies operating in oncology drugs, APIs, and cancer care could benefit from this long-term trend.
As oncology continues to outpace the broader pharma industry, these three Indian small- and mid-cap companies could be among the key beneficiaries.🧵
1/5 Why is oncology becoming such an attractive opportunity?
-Global cancer cases are projected to rise from 20 million in 2022 to 35.3 million by 2050 (+76%).
- High entry barriers, complex manufacturing, and stringent regulatory approvals make oncology difficult to replicate.
- As a result, oncology spending is growing at ~12% annually, significantly faster than the broader pharma industry.
2/5 Shilpa Medicare Ltd
-Oncology is the core of Shilpa's business, with oncology APIs contributing ₹390 crore in FY26 and accounting for ~51% of its API revenue. Management describes oncology as the "bedrock" of the company.
- The company is one of the leading suppliers of oncology APIs and formulations, serving 50+ countries through a vertically integrated model spanning APIs to finished formulations.
-To capitalize on the growing oncology opportunity, Shilpa is adding 15+ new oncology APIs targeting blockbuster drugs facing patent expiries through 2032, while oncology API revenue grew ~20% YoY in FY26.
India's e-commerce might explode to $80 billion by 2030.
This is powered by ultra-fast delivery wars.
But who wins the race?
Bernstein's fresh report on Eternal and Swiggy uncovers surprising shifts - slowing food growth, quick commerce battles, and hidden options.
Let’s discuss in this thread 🧵
Bernstein spotlights India's top 5% - 70 million urban consumers boasting $20,000 GDP per capita, controlling an $80 billion wallet by FY30.
Platforms like Eternal and Swiggy are morphing into lifestyle concierges, bundling quick commerce, food delivery, dining, and events to boost transaction frequency and wallet share through relentless innovation.
For context, this Serviceable Addressable Market (SAM) offers a 4x growth potential from FY25's $14 billion B2C GOV for these players.
Globally, markets consolidate fast:
Top 2-3 players grab 80-100% share in food delivery (97% in US, 99% in China) and 77-88% in e-commerce.
India's mirroring this, with scale in data and logistics trumping network effects.
Eternal leads here with its food delivery and quick commerce dominance, while Swiggy holds strong as #2, both leveraging 20-25 million unique daily active users to defend positions.
Chemical Industry insights & opportunities for investors from Mr. Anurag Surana's chat with Manish of Solidarity Advisors.
Mr Surana has 35+ yrs of experience. He was an investor & board member at PI Industries, having worked there for 14 years as Executive Director.
Thread🧵
1. A few years ago, Indian companies were small.
"20 years back, typically Indian companies were small, insignificant players... they were treated as raw material suppliers, not as strategic partners."
Cut to the 2020s, forget China plus one, many are now selling in China.
2. For the uninitiated, "China Plus One" strategy is a business tactic where companies diversify their supply chains & production by investing in suppliers from countries other than China to reduce risks and over-reliance on China.
This strategy gained momentum due to increasing costs, trade tensions, geopolitical uncertainties & the significant disruptions caused by the COVID-19 pandemic.